Page 35 - Abt News Today

Arcblock (ABT) traded 8.1% higher against the US dollar during the 24-hour period ending at 9:00 AM E.T. on January 29th. One Arcblock token can currently be purchased for $0.26 or 0.00000625 BTC on major exchanges. Arcblock has a total market cap of $25.82 million and $1.04 million worth of Arcblock was traded on exchanges […]

Savant Capital LLC raised its position in Abbott Laboratories (NYSE:ABT – Free Report) by 2.5% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 106,921 shares of the healthcare product maker’s stock after acquiring an additional 2,595 shares during the period. […]

Palisade Asset Management LLC increased its stake in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 0.2% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 207,608 shares of the healthcare product maker’s stock after purchasing an additional 454 shares during the period. Abbott Laboratories accounts […]

Van Cleef Asset Management Inc decreased its stake in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 11.3% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 6,000 shares of the healthcare product maker’s stock after selling 764 shares during the quarter. Van Cleef Asset Management Inc’s holdings in Abbott Laboratories were worth $581,000 […]

Metis Global Partners LLC boosted its holdings in Abbott Laboratories (NYSE:ABT – Free Report) by 20.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 73,139 shares of the healthcare product maker’s stock after acquiring an additional 12,199 shares during the […]

Abbott Laboratories (NYSE:ABT – Get Free Report) had its price target hoisted by equities research analysts at Citigroup from $123.00 to $126.00 in a research note issued to investors on Thursday, Benzinga reports. The firm currently has a “buy” rating on the healthcare product maker’s stock. Citigroup’s price objective would suggest a potential upside of […]

Abbott Laboratories (NYSE:ABT – Get Free Report)‘s stock had its “outperform” rating reaffirmed by equities researchers at Royal Bank of Canada in a research report issued to clients and investors on Thursday, Marketbeat reports. They presently have a $128.00 price target on the healthcare product maker’s stock. Royal Bank of Canada’s price target would suggest […]

Global Wealth Management Investment Advisory Inc. raised its position in Abbott Laboratories (NYSE:ABT – Free Report) by 25.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,076 shares of the healthcare product maker’s stock after purchasing an additional 215 shares during the quarter. […]

Abbott Laboratories (NYSE:ABT – Get Free Report) had its price objective increased by analysts at Citigroup from $123.00 to $126.00 in a research report issued on Thursday, Benzinga reports. The firm currently has a “buy” rating on the healthcare product maker’s stock. Citigroup’s price target suggests a potential upside of 12.49% from the company’s previous […]

Callan Capital LLC raised its holdings in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 33.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,104 shares of the healthcare product maker’s stock after buying an additional 1,018 shares […]